Navigation Links
Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Date:5/18/2011

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival (the primary endpoint of the study) and time-to-progression. The study evaluated Nexavar in combination with a chemotherapeutic agent, either gemcitabine or capecitabine. The data will be presented on June 6, 2011, at 11:45 a.m. during the oral abstract session at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

Clifford Hudis, M.D., Chief of the Breast Cancer Medicine Service and attending physician at the Memorial Sloan-Kettering Cancer Center, as well as Professor of Medicine at Weill Cornell Medical College, reported that patients receiving Nexavar in addition to standard chemotherapy agents obtained a progression-free survival benefit with median of 3.4 months to progression versus 2.7 (HR=0.65, one-sided p-value=0.01). Time-to-progression was similarly improved from a median of 3.6 months from 2.7 (HR=0.64; one-sided p-value=0.009) in this pre-treated population.

"These results demonstrate the importance of continuing to evaluate antiangiogenic compounds in breast cancer, and their study should remain a high priority for the research community," said Dr. Hudis.

"These data are similar to those observed in our previous Phase 2 trial evaluating Nexavar in combination with capecitabine," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations for Onyx Pharmaceuticals.  "Onyx and Baye
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
2. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
3. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
4. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
5. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
6. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
7. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
8. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
9. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
10. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
11. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
(Date:7/29/2014)... 29, 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. The study finds that ...
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Drew Crawford Announces Launch of PBM365 Media 2
... Test builds on company,s suite of tests to ... Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing ... new diagnostic assay designed to help physicians better ... infections. The company will introduce the Pneumococcal ...
... of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI ... Given With Standard Platelet TherapyKENILWORTH, N.J., March 12 ... ) Phase II trial of SCH 530348, a novel ... The Lancet and demonstrated that the investigational ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
(Date:7/29/2014)... Regardless of the good things that happen in ... those with. Love is about understanding, commitment and sharing ... also about overcoming all the challenges that a relationship ... women need to know how to understand guys. ... please visit the official website at http://www.dailygossip.org/enchant-him-review-7111 . ...
(Date:7/29/2014)... Daily Gossip indicates in its Acne No More ... beautiful and clear skin in just 30 to 60 days. ... results even sooner than that. The new method was created ... step by step program, too. , Mike Walden claimed ... battled this condition for a decade and none of the ...
(Date:7/29/2014)... (HealthDay News) --,The time at which heart attack patients ... survival, new research suggests. Showing up at the ... is associated with a 13 percent higher risk for ... Every year, more than 250,000 people suffer a ... heart attack, which is caused by a complete blockage ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Chlorine helps keep pool ... likely to develop eye infections, doctors say. ... well as blurry vision, said Dr. Sampson Davis, an ... New Jersey. It,s important to understand why this ... away the outer film layer of the eye that ...
Breaking Medicine News(10 mins):Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Acne No More Review Reveals Most Effective Acne Cure Program 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Protect Your Eyes When Hitting the Pool 2
... serious complications, researchers say , THURSDAY, Oct. 22 (HealthDay ... scans are better than standard X-rays at detecting the ... known as swine flu. , Researchers examined seven patients ... all of them. Three of the patients also received ...
... social interaction, researchers say , WEDNESDAY, Oct. 21 (HealthDay ... with autism has been identified by U.S. researchers, who ... diagnose and treat the disorder. , This genetic signature ... to the way that genes are switched on and ...
... to new treatments , WEDNESDAY, Oct. 21 (HealthDay News) ... that the gene behind Gaucher disease, a rare neurological ... those of us who work with rare disorders, it ... applicable to more common disorders," said Dr. Ellen Sidransky, ...
... women have tougher time shedding those excess pounds, study finds ... gain more than 15 pounds during pregnancy tend to retain ... finds. , Oregon researchers collected data on almost 1,700 obese ... gave birth between 2000 and 2005. , "We found that ...
... plans to rethink testing for breast, prostate tumors, contrary ... -- The American Cancer Society says it is not ... widely reported Wednesday. , "We are not redoing or ... going to restate our guidelines to emphasize the inadequacies ...
... Ohio It was once thought that the two communities ... cells and the normal cells that surround them existed ... cells encouraged cells within the tumor to become malignant, but ... new study led by Ohio State University cancer researchers published ...
Cached Medicine News:Health News:Less Sensitivity to Hormone May Play Role in Autism 2Health News:Gene Behind Gaucher Disease a Player in Parkinson's 2Health News:Gene Behind Gaucher Disease a Player in Parkinson's 3Health News:For Obese, Weight Gained in Pregnancy May Not Leave 2Health News:For Obese, Weight Gained in Pregnancy May Not Leave 3Health News:American Cancer Society Stands By Cancer Screening Guidelines 2Health News:American Cancer Society Stands By Cancer Screening Guidelines 3Health News:American Cancer Society Stands By Cancer Screening Guidelines 4Health News:Study shows how normal cells influence tumor growth 2
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
... planned ECCE with peristaltic pump with ... suction, reflux possible with multi-function footswitch ... all critical functions. You can also ... actual vacuum level indicated by Bar ...
Medicine Products: